ADVERTISEMENT
Bliss GVS Pharma’s Maharashtra Facility Clears U.S. FDA Inspection
The inspection by the U.S. Food and Drug Administration was conducted from June 17-20, Bliss GVS Pharma said in a statement.
08 Oct 2019, 07:34 PM IST 
Pills are arranged for a photograph at a pharmacy in U.S. (Photographer: Daniel Acker/Bloomberg)
Drug firm Bliss GVS Pharma Ltd. has said its subsidiary Kremoint Pharma has cleared an inspection of its Ambernath facility in Maharashtra by the U.S. health regulator.
The inspection by the U.S. Food and Drug Administration was conducted from June 17-20, Bliss GVS Pharma said in a statement.
"The successful audit outcome from U.S. FDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma Vice President-Strategy and Business Development Gagan Harsh Sharma said.
This along with the completion of company's oral solid dosage manufacturing unit located at Palghar (Maharashtra) will further boost its growth into new geographies, he added.